Drug Development Pipeline
This program is exploring polymer nanoparticles, a type of delivery vehicle that could be used to carry genetic therapies into the lung. Compared to other delivery vehicles, these polymer nanoparticles could more accurately target lung cells and potentially better resist the thick, sticky mucus that clogs the lungs of people with CF.
At first, Nanite will work on developing polymer nanoparticles that can deliver messenger RNA (mRNA) therapy into the lungs. Delivery of mRNA would allow lung cells to make full-length, functional CFTR protein, regardless of an individual’s CFTR mutations. Eventually, Nanite hopes these nanoparticles can be used to deliver other types of genetic therapies, such as gene therapy or gene editing, and target other organs affected by CF, such as the pancreas.
Laboratory studies to develop and test this technology are underway.
This program is sponsored by Nanite Inc. and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More